INBX
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx Biosciences, Inc. (INBX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | C- (1.9) | F (0.3) | C+ (2.5) | C+ (2.6) | C- (2.0) |
| 2026-11-05 | C+ (2.5) | C- (1.9) | F (0.3) | C+ (2.6) | C+ (2.7) | C- (2.0) |
| 2026-10-29 | C+ (2.5) | D+ (1.8) | F (0.3) | C+ (2.7) | C+ (2.7) | C- (2.0) |
| 2026-10-22 | C+ (2.5) | D+ (1.8) | F (0.3) | B- (2.9) | C+ (2.6) | C- (2.0) |
| 2026-10-15 | C+ (2.5) | D+ (1.8) | F (0.3) | B- (3.1) | C+ (2.6) | C- (2.1) |